Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-negative Tumor”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Large-scale testing (Phase 3)Enrolling By InvitationNCT05645536
What this trial is testing

Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

Who this might be right for
Breast Cancer
Tolmar Inc. 250
Testing effectiveness (Phase 2)Study completedNCT02102490
What this trial is testing

Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

Who this might be right for
Metastatic Breast Cancer
Eli Lilly and Company 132
Not applicableStudy completedNCT07072013
What this trial is testing

An Indirect Treatment Comparison of the Effectiveness of Ribociclib Combined With Non-steroidal Aromatase Inhibitors vs. Tamoxifen for the Adjuvant Treatment of Premenopausal Women With Hormon Receptor-positive, HER2-negative Early Breast Cancer

Who this might be right for
Breast Cancer
Novartis Pharmaceuticals 1,937
Testing effectiveness (Phase 2)Study completedNCT00463788
What this trial is testing

Cetuximab and Cisplatin in the Treatment of "Triple Negative" (Estrogen Receptor [ER] Negative, Progesterone Receptor [PgR] Negative, and Human Epidermal Growth Factor Receptor 2 [HER2] Negative) Metastatic Breast Cancer

Who this might be right for
Breast Neoplasm
Merck KGaA, Darmstadt, Germany 181
Testing effectiveness (Phase 2)Study completedNCT01730612
What this trial is testing

ImmunoTEP au 68-Ga- IMP-288 for Patients With a Recurrence of HER2 Negative Breast Carcinoma Expressing CEA

Who this might be right for
HER2 Negative Breast Carcinoma Expressing CEA
Nantes University Hospital 23
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06888037
What this trial is testing

Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer

Who this might be right for
Gastric AdenocarcinomaGEJ AdenocarcinomaFirst-line Therapy+3 more
Ruijin Hospital 55
Not applicableStudy completedNCT05132101
What this trial is testing

Analysis of the Real-world Prescription Pattern of Palbociclib Combination Therapy With Aromatase Inhibitor as a First Line Therapy in Metastatic Breast Cancer Patients Using the National Health Insurance Claims Data in South Korea

Who this might be right for
Metastatic Breast Cancer
Pfizer 2,758
Testing effectiveness (Phase 2)UnknownNCT05044988
What this trial is testing

HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Who this might be right for
HR+/HER2- Advanced and/or Metastatic Breast Cancer
Jiangsu Hansoh Pharmaceutical Co., Ltd. 20
Testing effectiveness (Phase 2)Looking for participantsNCT06516289
What this trial is testing

Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab

Who this might be right for
BRCA-Mutated Breast CarcinomaHER2-negative Breast Cancer
Fudan University 130
Large-scale testing (Phase 3)Study completedNCT03337724
What this trial is testing

Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 579
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07767474
What this trial is testing

Evaluate ATX-898 in Participants With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Antares Therapeutics, Inc 343
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06462079
What this trial is testing

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

Who this might be right for
Brain Metastasis
Guangzhou Medical University 43
Testing effectiveness (Phase 2)Study completedNCT05659563
What this trial is testing

Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%

Who this might be right for
Breast CancerBreast Cancer, Early-Onset
MedSIR 92
Early research (Phase 1)Study completedNCT02364492
What this trial is testing

A Phase I Study of a Therapeutic Vaccine Candidate in Patients With Localized Breast Cancer at High-Risk of Relapse

Who this might be right for
Breast Neoplasms
Institut Pasteur 20
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07113964
What this trial is testing

QL1706 With Olaparib for Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

Who this might be right for
Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
The First Affiliated Hospital with Nanjing Medical University 79
Not applicableStudy completedNCT02688998
What this trial is testing

REaCT-vascular Access Her2 Negative Vascular Access Strategies for (Neo) Adjuvant Breast Cancer Treatment Without Trastuzumab

Who this might be right for
Breast CancerCancer
Ottawa Hospital Research Institute 150
Large-scale testing (Phase 3)Not Yet RecruitingNCT07153757
What this trial is testing

De-escalation Therapy in Stage I ER-Positive Breast Cancer: A Non-Inferiority Trial

Who this might be right for
Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Fudan University 2,934
Not applicableStudy completedNCT05217381
What this trial is testing

Real-World Data of Clinicopathological Characteristics and Management of Breast Cancer Patients According to HER2 Status

Who this might be right for
Early Breast CancerMetastatic Breast CancerLocally Advanced Breast Cancer
MedSIR 18,533
Large-scale testing (Phase 3)Study completedNCT02028507
What this trial is testing

Phase III Palbociclib With Endocrine Therapy vs. Capecitabine in HR+/HER2- MBC With Resistance to Aromatase Inhibitors

Who this might be right for
Metastatic Breast Cancer
Spanish Breast Cancer Research Group 693
Not applicableLooking for participantsNCT06222957
What this trial is testing

The Effects of HER2 Receptor Signaling on Human Brown Fat Activity

Who this might be right for
Breast Cancer
Rigshospitalet, Denmark 30
Next Page